Metabolic Solutions Development Company
Pharmaceuticals, 161 E Ave, Kalamazoo, Michigan, 49007, United States, 11-50 Employees
Phone Number: 26********
Who is METABOLIC SOLUTIONS DEVELOPMENT COMPANY
Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondri...
Read More
-
Headquarters: 161 E Michigan Ave, Kalamazoo, Michigan, 49007, United States
-
Date Founded: 2006
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2833
|
NAICS Code: 339999 |
Show More
Does something look wrong? Fix it. | View contact records from METABOLIC SOLUTIONS DEVELOPMENT COMPANY
Metabolic Solutions Development Company Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Metabolic Solutions Development Company
Answer: Metabolic Solutions Development Company's headquarters are located at 161 E Ave, Kalamazoo, Michigan, 49007, United States
Answer: Metabolic Solutions Development Company's phone number is 26********
Answer: Metabolic Solutions Development Company's official website is https://msdrx.com
Answer: Metabolic Solutions Development Company's revenue is $1 Million to $5 Million
Answer: Metabolic Solutions Development Company's SIC: 2833
Answer: Metabolic Solutions Development Company's NAICS: 339999
Answer: Metabolic Solutions Development Company has 11-50 employees
Answer: Metabolic Solutions Development Company is in Pharmaceuticals
Answer: Metabolic Solutions Development Company contact info: Phone number: 26******** Website: https://msdrx.com
Answer: Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimers disease and Parkinsons disease, as well certain genetic diseases such as polycystic kidney disease. MSDC was founded in 2006 by Jerry Colca, PhD and Rolf Kletzien, PhD, former researchers at The Upjohn Company who were among the original researchers in the field of insulin sensitizers, and who selected and led the early development of Actos (pioglitazone). The company is headquartered in Kalamazoo, Michigan.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month